Gland Pharma reports Q2 FY26 PAT higher at Rs. 184 Cr
Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal
Revenue for the quarter rose 5.8% to Rs. 1,487 crore as compared to Rs. 1,406 crore in the corresponding quarter of the previous fiscal
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
The new CMC Process R&D Center represents a strategic investment in scale, sustainability, and specialization
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Vaccine efficacy against primary CMV infection ranged from 6 per cent to 23 per cent, depending on case definition, falling short of Moderna’s predefined target
The initial $100 million will fund a state-of-the-art hard-shell capsule facility in Atlanta
Subscribe To Our Newsletter & Stay Updated